SMARCA4 and cancer: They note that SMARCA4 inactivation resulted in greater incorporation of non‐essential SMARCA2 subunits into the SWI/SNF complexes, revealing a role for SMARCA2 in oncogenesis induced by SMARCA4 loss, and they identified that ATPase and bromodomain‐containing SMARCA2 may serve as potential therapeutic targets in these cancers.